Central Alerting System
View Alert


Originator: DHSC & NHS England and Improvement: Supply disruption alert

Issue date: 22-Apr-2020 13:51:02

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • DHSC Supply Disruption - Medicines

Action category: Immediate Action

Title: Renal replacement therapy in critical care: severe disruption to the supply of kits and fluids to perform continuous vein to vein haemofiltration including haemodiafiltration

Broadcast content:

There are now limited supplies of certain haemofiltration sets and fluids in the system, due to the recent increase in demand during the Covid-19 pandemic.

This alert contains advice on the management of affected patients.

Given the links to covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type. 

Please note that no response is required via the CAS website to this alert.



Additional information: This alert is not relevant to primary care.

Alert reference: SDA/2020/005

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency